Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats

Psychopharmacology

Volumn 186, Issue 2, 2006, Pages 209-217

  Zhang, Han Ting ^a   Zhao, Yu ^b   Huang, Ying ^a   Deng, Chengjun ^c   Hopper, Allen T ^c   De Vivo, Michael ^c   Rose, Gregory M ^c   O'Donnell, James M ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c Memory Pharmaceuticals Corporation   (United States)

Author keywords

Antidepressant; Behavior; DRL; Drug discrimination; Forced swim; PDE4 inhibitor; Phosphodiesterase; Rolipram binding site

Indexed keywords

4 [2 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL] 2 PHENYLETHYL]PYRIDINE; MEM 1018; MEM 1091; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PICLAMILAST; ROLIPRAM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; BINDING AFFINITY; BINDING COMPETITION; CONTROLLED STUDY; DRUG BINDING; DRUG CONFORMATION; DRUG DISCRIMINATION; ENZYME CONFORMATION; FORCED SWIMMING TEST; INSTRUMENTAL CONDITIONING; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BINDING, COMPETITIVE; MALE; PHOSPHODIESTERASE INHIBITORS; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; ROLIPRAM;

EID: 33646542713     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-006-0369-4     Document Type: Article

References (34)

1. Asanuma M, Nishibayashi S, Iwata E, Kondo Y, Nakanishi T, Vargas MG, Ogawa N (1996) Alterations of cAMP response element-binding activity in the aged rat brain in response to administration of rolipram, a cAMP-specific phosphodiesterase inhibitor. Brain Res Mol Brain Res 41:210-215
2. Brucato FH, Hopper AT, Cook KQ, Chanas B, Deng CJ, Fiorino DF (2005) PDE4 inhibitor affinity at the high affinity rolipram binding site (HARBS) predicts efficacy in the rat pup ultrasonic vocalization model. Program No. 1024.12. Abstract Viewer/Itinerary Planner. Society for Neuroscience, Washington, District of Columbia
3. Cheng Y, Prusoff WH (1973) Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50% inhibition (150) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108
4. Conti M, Richter W, Mehats C, Livera G, Park JY, Jin C (2003) Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278:5493-5496
5. Cooper N, Teixeira MM, Warneck J, Miotla JM, Wills RE, Macari DM, Gristwood RW, Hellewell PG (1999) A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo. Br J Pharmacol 126:1863-1871
6. Duplantier AJ, Biggers MS, Chambers RJ, Cheng JB, Cooper K, Damon DB, Eggler JF, Kraus KG, Marfat A, Masamune H, Pillar JS, Shirley JT, Umland JP, Watson JW (1996) Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret. J Med Chem 39:120-125
7. Houslay MD, Adams DR (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370:1-18
8. Jacobitz S, McLaughlin MM, Livi GP, Burman M, Torphy TJ (1996) Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding. Mol Pharmacol 50:891-899
9. Kaulen P, Bruning G, Schneider HH, Sarter M, Baumgarten HG (1989) Autoradiographic mapping of a selective cyclic adenosine monophosphate phosphodiesterase in rat brain with the antidepressant [3H]rolipram. Brain Res 503:229-245
10. Li C, Chauret N, Trimble LA, Nicoll-Griffith DA, Silva JM, MacDonald D, Perrier H, Yergey JA, Parton T, Alexander RP, Warrellow GJ (2001) Investigation of the in vitro metabolism profile of a phosphodiesterase-IV inhibitor, CDP-840: leading to structural optimization. Drug Metab Dispos 29:232-241
11. Makhay MM, Houslay MD, O'Donnell JM (2001) Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats. Psychopharmacology (Berl) 158:297-304
12. Nakamura K, Ikoma Y, Kimura K, Nakada Y, Kobayashi S, Yamaguchi M, Nakagawa H (1989) Effects in animal models of depression of lisuride alone and upon coadministration with antidepressants. Nippon Yakurigaku Zasshi 94:81-89
13. O'Donnell JM (1993) Antidepressant-like effects of rolipram and other inhibitors of cyclic adenosine monophosphate phosphodiesterase on behavior maintained by differential reinforcement of low response rate. J Pharmacol Exp Ther 264:1168-1178
14. O'Donnell JM, Frith S (1999) Behavioral effects of family-selective inhibitors of cyclic nucleotide phosphodiesterases. Pharmacol Biochem Behav 63:185-192
15. O'Donnell JM, Zhang HT (2004) Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4). Trends Pharmacol Sci 25:158-163
16. O'Donnell JM, Wolfe BB, Frazer A (1984) Agonist interactions with beta adrenergic receptors in rat brain. J Pharmacol Exp Ther 228:640-647
17. Ortmann R, Meisburger JG (1986) Rolipram forms a potent discriminative stimulus in drug discrimination experiments in rats. Psychopharmacology (Berl) 89:273-277
18. Page ME, Detke MJ, Dalvi A, Kirby LG, Lucki I (1999) Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology (Berl) 147:162-167
19. Renau TE (2004) The potential of phosphodiesterase 4 inhibitors for the treatment of depression: opportunities and challenges. Curr Opin Investig Drugs 5:34-39
20. Reneric JP, Lucki I (1998) Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacology (Berl) 136:190-197
21. Schmiechen R, Schneider HH, Wachtel H (1990) Close correlation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase. Psychopharmacol Ser (Berl) 102:17-20
22. Schneider HH, Schmiechen R, Brezinski M, Seidler J (1986) Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol 127:105-115
23. Soto FJ, Hanania NA (2005) Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease. Curr Opin Pulm Med 11:129-134
24. Souness JE, Rao S (1997) Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal 9:227-236
25. Souness JE, Houghton C, Sardar N, Withnall MT (1997) Evidence that cyclic AMP phosphodiesterase inhibitors suppress interleukin-2 release from murine splenocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer. Br J Pharmacol 121:743-750
26. Zhang HT, Crissman AM, Dorairaj NR, Chandler LJ, O'Donnell JM (2000) Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism. Neuropsychopharmacology 23:198-204
27. Zhang HT, Frith SA, Wilkins J, O'Donnell JM (2001) Comparison of the effects of isoproterenol administered into the hippocampus, frontal cortex, or amygdala on behavior of rats maintained by differential reinforcement of low response rate. Psychopharmacology (Berl) 159:89-97
28. Zhang HT, Huang Y, Jin SL, Frith SA, Suvarna N, Conti M, O'Donnell JM (2002) Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology 27:587-595
29. Zhang HT, Huang Y, O'Donnell JM (2003) Antagonism of the antidepressant-like effects of clenbuterol by central administration of beta-adrenergic antagonists in rats. Psychopharmacology (Berl) 170:102-107
30. Zhang HT, Zhao Y, Huang Y, Dorairaj NR, Chandler LJ, O'Donnell JM (2004) Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by Infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus. Neuropsychopharmacology 29:1432-1439
31. Zhang HT, Huang Y, Suvarna NU, Deng C, Crissman AM, Hopper AT, De Vivo M, Rose GM, O'Donnell JM (2005a) Effects of the novel PDE4 inhibitors MEM1018 and MEM1091 on memory in the radial-arm maze and inhibitory avoidance tests in rats. Psychopharmacology (Berl) 179:613-619
32. Zhang HT, Huang Y, Mishler K, Roerig SC, O'Donnell JM (2005b) Interaction between the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDE inhibitor rolipram in rats. Psychopharmacology (Berl) 182:104-115
33. Zhao Y, Zhang HT, O'Donnell JM (2003a) Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]piclamilast and [3H]rolipram. J Pharmacol Exp Ther 305:565-572
34. Zhao Y, Zhang HT, O'Donnell JM (2003b) Antidepressant-induced increase in high-affinity rolipram binding sites in rat brain: dependence on noradrenergic and serotonergic function. J Pharmacol Exp Ther 307:246-253